ReviewFrontiers in pharmacology2026
Mechanisms of mitochondrial dysfunction and protective strategies in skin flap ischemia-reperfusion injury.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Flap transplantation remains a cornerstone of reconstruction of complex tissue defects and restoration of local form and function. However, ischemia-reperfusion (I/R) injury continues to compromise flap viability and is a major cause of distal necrosis. Emerging evidence suggests that mitochondria are among the earliest and most severely affected organelles during flap I/R, placing them at the center of tissue injury. Once disrupted, mitochondrial dysfunction may aggravate microcirculatory failure, amplify inflammatory responses, and accelerate tissue damage through excessive mitochondrial reactive oxygen species (mtROS) generation, mitochondrial permeability transition pore (mPTP) opening, loss of mitochondrial membrane potential, and impaired mitochondrial quality control. Disruption of mitochondrial homeostasis also reshapes the behavior of endothelial cells, macrophages, fibroblasts, and vascular smooth muscle cells, thereby influencing flap repair outcomes. In this review, we focus on mitochondrial homeostasis as a unifying framework for understanding flap I/R injury. We discuss its involvement in oxidative stress, calcium overload, mPTP opening, metabolic dysfunction, defective mitochondrial quality control, and mitochondria-related programmed cell death. We further summarize recent therapeutic strategies designed to preserve or restore mitochondrial homeostasis, with the goal of informing future approaches to improve flap survival and tissue repair.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.